Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,accountsPayable,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,totalCashflowsFromInvestingActivities,otherCashflowsFromInvestingActivities,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,ENTX,7008000.0,23776800,1159000,,-9450000,,-9488000,1309000,99000,-2359000,-2359000,-10000,,,,,38000,157000,2516000,58000,-7091000,,-9488000,-9488000,605000.0,80827000.0,10914000.0,7613000.0,9994000.0,18527000.0,1038000.0,-82383000.0,78000.0,9169000.0,16381000.0,10616000.0,9169000.0,488000.0,17434000.0,15000.0,440000.0,133000.0,-45000.0,10064000.0,-663000.0,10109000.0,7788000.0,-2276000.0,91000.0,240000.0,7411000.0,,,,6818000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,Entera Bio Ltd.,False,False,NCM,5.14,1630509443,0.25999975,4.92,5.179,4.88,66484,REGULAR,0,2,5.3278637,4.88 - 5.179,4.88,5.02,5.07,9,12,finmb_106997294,Entera Bio Ltd.,NasdaqCM,USD,3161829,119066,4.14,4.14,1.0 - 10.16,-5.02,-0.4940945,1.0,10.16,1621508340,1629289800,1629721800,-0.862,-0.57,-0.84,-6.1190476,0.32,5.17,-0.03000021,-0.0058027483,4.011667,1.1283331,0.2812629,122212752,-9.017544,16.0625,15,America/New_York,EDT,-14400000,1.69,,,10.16,1.0,5.17,4.01,3.16M,119.07k,23.78M,,13.62M,31.53%,23.73%,119.25k,0.22,0.52%,0.50%,697.1k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-2,273.13%",-40.46%,-187.80%,480k,0.03,273.80%,156k,-10.79M,-16.55M,-0.86,,16.38M,0.69,402k,5.28,1.64,0.32,-10.04M,-410.25k,Value,9122002,Healthcare,19,"Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.",Jerusalem,972 2 532 7151,1609372800,Israel,http://www.enterabio.com,86400,Kiryat Hadassah Minrav Building,Biotechnology,Fifth Floor Kiryat Hadassah PO Box 12117
t-1,ENTX,6060000.0,23776800,1176000,,-2231000,,-2251000,1235000,116000,-2295000,-2295000,-10000,-50000.0,,,,20000,221000,2516000,105000,64000,,-2251000,-2251000,605000.0,70595000.0,3597000.0,6665000.0,1590000.0,10262000.0,163000.0,-72895000.0,81000.0,8965000.0,8593000.0,3273000.0,8965000.0,548000.0,9109000.0,255000.0,164000.0,111000.0,-23000.0,2953000.0,831000.0,2976000.0,1525000.0,-1393000.0,73000.0,-255000.0,98000.0,-35000.0,-33000.0,-2000.0,5836000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,Entera Bio Ltd.,False,False,NCM,5.14,1630509443,0.25999975,4.92,5.179,4.88,66484,REGULAR,0,2,5.3278637,4.88 - 5.179,4.88,5.02,5.07,9,12,finmb_106997294,Entera Bio Ltd.,NasdaqCM,USD,3161829,119066,4.14,4.14,1.0 - 10.16,-5.02,-0.4940945,1.0,10.16,1621508340,1629289800,1629721800,-0.862,-0.57,-0.84,-6.1190476,0.32,5.17,-0.03000021,-0.0058027483,4.011667,1.1283331,0.2812629,122212752,-9.017544,16.0625,15,America/New_York,EDT,-14400000,1.69,,,10.16,1.0,5.17,4.01,3.16M,119.07k,23.78M,,13.62M,31.53%,23.73%,119.25k,0.22,0.52%,0.50%,697.1k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-2,273.13%",-40.46%,-187.80%,480k,0.03,273.80%,156k,-10.79M,-16.55M,-0.86,,16.38M,0.69,402k,5.28,1.64,0.32,-10.04M,-410.25k,Value,9122002,Healthcare,19,"Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.",Jerusalem,972 2 532 7151,1609372800,Israel,http://www.enterabio.com,86400,Kiryat Hadassah Minrav Building,Biotechnology,Fifth Floor Kiryat Hadassah PO Box 12117
t-2,ENTX,5135000.0,23776800,1606000,,-1624000,,-1624000,1143000,19000,-2730000,-2730000,-10000,-13000.0,,,,0,50000,2780000,31000,1106000,,-1624000,-1624000,605000.0,67176000.0,3040000.0,5740000.0,2661000.0,8780000.0,722000.0,-70644000.0,75000.0,9208000.0,7068000.0,2916000.0,9208000.0,385000.0,7790000.0,,88000.0,-11000.0,-41000.0,171000.0,-388000.0,212000.0,-2699000.0,-2848000.0,51000.0,-255000.0,-876000.0,-22000.0,-33000.0,-22000.0,4874000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,Entera Bio Ltd.,False,False,NCM,5.14,1630509443,0.25999975,4.92,5.179,4.88,66484,REGULAR,0,2,5.3278637,4.88 - 5.179,4.88,5.02,5.07,9,12,finmb_106997294,Entera Bio Ltd.,NasdaqCM,USD,3161829,119066,4.14,4.14,1.0 - 10.16,-5.02,-0.4940945,1.0,10.16,1621508340,1629289800,1629721800,-0.862,-0.57,-0.84,-6.1190476,0.32,5.17,-0.03000021,-0.0058027483,4.011667,1.1283331,0.2812629,122212752,-9.017544,16.0625,15,America/New_York,EDT,-14400000,1.69,,,10.16,1.0,5.17,4.01,3.16M,119.07k,23.78M,,13.62M,31.53%,23.73%,119.25k,0.22,0.52%,0.50%,697.1k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-2,273.13%",-40.46%,-187.80%,480k,0.03,273.80%,156k,-10.79M,-16.55M,-0.86,,16.38M,0.69,402k,5.28,1.64,0.32,-10.04M,-410.25k,Value,9122002,Healthcare,19,"Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.",Jerusalem,972 2 532 7151,1609372800,Israel,http://www.enterabio.com,86400,Kiryat Hadassah Minrav Building,Biotechnology,Fifth Floor Kiryat Hadassah PO Box 12117
t-3,ENTX,6624000.0,23776800,2011000,,-3190000,,-3190000,1537000,21000,-3527000,-3527000,-10000,-29000.0,,,,0,52000,3579000,31000,337000,,-3190000,-3190000,605000.0,65740000.0,4233000.0,7229000.0,3859000.0,11462000.0,677000.0,-69020000.0,75000.0,10509000.0,9767000.0,4077000.0,10509000.0,413000.0,10444000.0,,49000.0,-434000.0,-35000.0,-35000.0,2000.0,212000.0,-3561000.0,-3526000.0,51000.0,-255000.0,45000.0,-22000.0,-33000.0,-22000.0,6367000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,Entera Bio Ltd.,False,False,NCM,5.14,1630509443,0.25999975,4.92,5.179,4.88,66484,REGULAR,0,2,5.3278637,4.88 - 5.179,4.88,5.02,5.07,9,12,finmb_106997294,Entera Bio Ltd.,NasdaqCM,USD,3161829,119066,4.14,4.14,1.0 - 10.16,-5.02,-0.4940945,1.0,10.16,1621508340,1629289800,1629721800,-0.862,-0.57,-0.84,-6.1190476,0.32,5.17,-0.03000021,-0.0058027483,4.011667,1.1283331,0.2812629,122212752,-9.017544,16.0625,15,America/New_York,EDT,-14400000,1.69,,,10.16,1.0,5.17,4.01,3.16M,119.07k,23.78M,,13.62M,31.53%,23.73%,119.25k,0.22,0.52%,0.50%,697.1k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-2,273.13%",-40.46%,-187.80%,480k,0.03,273.80%,156k,-10.79M,-16.55M,-0.86,,16.38M,0.69,402k,5.28,1.64,0.32,-10.04M,-410.25k,Value,9122002,Healthcare,19,"Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.",Jerusalem,972 2 532 7151,1609372800,Israel,http://www.enterabio.com,86400,Kiryat Hadassah Minrav Building,Biotechnology,Fifth Floor Kiryat Hadassah PO Box 12117
